This article is rated C-class on Wikipedia's
content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||||||||||
|
Ideal sources for Wikipedia's health content are defined in the guideline
Wikipedia:Identifying reliable sources (medicine) and are typically
review articles. Here are links to possibly useful sources of information about Amifampridine.
|
Hello fellow Wikipedians,
I have just added archive links to one external link on
3,4-Diaminopyridine. Please take a moment to review
my edit. If necessary, add {{
cbignore}}
after the link to keep me from modifying it. Alternatively, you can add {{
nobots|deny=InternetArchiveBot}}
to keep me off the page altogether. I made the following changes:
When you have finished reviewing my changes, please set the checked parameter below to true to let others know.
An editor has reviewed this edit and fixed any errors that were found.
Cheers.— cyberbot II Talk to my owner:Online 14:41, 18 January 2016 (UTC)
These two sentences were moved to Talk as they are not supported by the references cited and appear to be incorrect. The first statement mistakes the a type of FDA citation ("483") with the number of citations. The second statement refers to a document which appears to endorse use of the free base for LEMS treatment despite the deficit of preclinical toxicology and pharmacology studies.
Stat2016
was invoked but never defined (see the
help page).